O	0	5	Phase
O	6	9	III
O	10	15	trial
O	16	18	of
B-intervention	19	29	epirubicin
I-intervention	30	34	plus
I-intervention	35	45	paclitaxel
O	46	54	compared
O	55	59	with
B-control	60	70	epirubicin
I-control	71	75	plus
I-control	76	92	cyclophosphamide
O	93	95	as
O	96	101	first
O	101	102	-
O	102	106	line
O	107	119	chemotherapy
O	120	123	for
O	124	134	metastatic
O	135	141	breast
O	142	148	cancer
O	148	149	:
B-location	150	156	United
I-location	157	164	Kingdom
O	165	173	National
O	174	180	Cancer
O	181	189	Research
O	190	199	Institute
O	200	205	trial
O	206	210	AB01
O	210	211	.

O	212	214	To
O	215	222	compare
O	223	226	the
O	227	240	effectiveness
O	241	244	and
O	245	257	tolerability
O	258	260	of
O	261	271	epirubicin
O	272	275	and
O	276	286	paclitaxel
O	287	288	(
O	288	290	EP
O	290	291	)
O	292	296	with
O	297	307	epirubicin
O	308	311	and
O	312	328	cyclophosphamide
O	329	330	(
O	330	332	EC
O	332	333	)
O	334	336	as
O	337	342	first
O	342	343	-
O	343	347	line
O	348	360	chemotherapy
O	361	364	for
O	365	375	metastatic
O	376	382	breast
O	383	389	cancer
O	390	391	(
O	391	394	MBC
O	394	395	)
O	395	396	.

B-eligibility	397	405	Patients
I-eligibility	406	416	previously
I-eligibility	417	426	untreated
I-eligibility	427	431	with
I-eligibility	432	444	chemotherapy
I-eligibility	445	446	(
I-eligibility	446	452	except
I-eligibility	453	456	for
I-eligibility	457	465	adjuvant
I-eligibility	466	473	therapy
I-eligibility	473	474	)
O	475	479	were
O	480	488	randomly
O	489	497	assigned
O	498	500	to
O	501	508	receive
O	509	515	either
O	516	518	EP
O	519	520	(
O	520	530	epirubicin
O	531	533	75
O	534	536	mg
O	536	537	/
O	537	539	m2
O	540	543	and
O	544	554	paclitaxel
O	555	558	200
O	559	561	mg
O	561	562	/
O	562	564	m2
O	564	565	)
O	566	568	or
O	569	571	EC
O	572	573	(
O	573	583	epirubicin
O	584	586	75
O	587	589	mg
O	589	590	/
O	590	592	m2
O	593	596	and
O	597	613	cyclophosphamide
O	614	617	600
O	618	620	mg
O	620	621	/
O	621	623	m2
O	623	624	)
O	625	637	administered
O	638	651	intravenously
O	652	657	every
O	658	659	3
O	660	665	weeks
O	666	669	for
O	670	671	a
O	672	679	maximum
O	680	682	of
O	683	686	six
O	687	693	cycles
O	693	694	.

O	695	698	The
O	699	706	primary
O	707	714	outcome
O	715	718	was
B-outcome-Measure	719	730	progression
I-outcome-Measure	730	731	-
I-outcome-Measure	731	735	free
I-outcome-Measure	736	744	survival
O	744	745	;
O	746	755	secondary
O	756	763	outcome
O	764	772	measures
O	773	777	were
B-outcome-Measure	778	785	overall
I-outcome-Measure	786	794	survival
O	794	795	,
B-outcome-Measure	796	804	response
I-outcome-Measure	805	810	rates
O	810	811	,
O	812	815	and
B-outcome-Measure	816	824	toxicity
O	824	825	.

O	826	833	Between
O	834	838	1996
O	839	842	and
O	843	847	1999
O	847	848	,
B-total-participants	849	852	705
O	853	861	patients
O	862	863	(
B-intervention-participants	863	866	353
O	867	869	EP
O	870	878	patients
O	879	882	and
B-control-participants	883	886	352
O	887	889	EC
O	890	898	patients
O	898	899	)
O	900	909	underwent
O	910	916	random
O	917	927	assignment
O	927	928	.

O	929	936	Patient
O	937	952	characteristics
O	953	957	were
O	958	962	well
O	963	970	matched
O	971	978	between
O	979	982	the
O	983	986	two
O	987	993	groups
O	993	994	,
O	995	998	and
O	999	1001	71
O	1001	1002	%
O	1003	1005	of
O	1006	1014	patients
O	1015	1023	received
O	1024	1027	six
O	1028	1034	cycles
O	1035	1037	of
O	1038	1047	treatment
O	1047	1048	.

B-outcome	1049	1058	Objective
I-outcome	1059	1067	response
I-outcome	1068	1073	rates
O	1074	1078	were
B-iv-bin-percent	1079	1081	65
I-iv-bin-percent	1081	1082	%
O	1083	1086	for
O	1087	1090	the
O	1091	1093	EP
O	1094	1099	group
O	1100	1103	and
B-cv-bin-percent	1104	1106	55
I-cv-bin-percent	1106	1107	%
O	1108	1111	for
O	1112	1115	the
O	1116	1118	EC
O	1119	1124	group
O	1125	1126	(
O	1126	1127	P
O	1128	1129	=
O	1130	1131	.
O	1131	1134	015
O	1134	1135	)
O	1135	1136	.

O	1137	1139	At
O	1140	1143	the
O	1144	1148	time
O	1149	1151	of
O	1152	1160	analysis
O	1160	1161	,
O	1162	1165	641
O	1166	1174	patients
O	1175	1176	(
O	1176	1178	91
O	1178	1179	%
O	1179	1180	)
O	1181	1184	had
B-outcome	1185	1189	died
O	1189	1190	.

B-outcome	1191	1197	Median
I-outcome	1198	1209	progression
I-outcome	1209	1210	-
I-outcome	1210	1214	free
I-outcome	1215	1223	survival
I-outcome	1224	1228	time
O	1229	1232	was
B-iv-cont-median	1233	1234	7
I-iv-cont-median	1234	1235	.
I-iv-cont-median	1235	1236	0
I-iv-cont-median	1237	1243	months
O	1244	1247	for
O	1248	1251	the
O	1252	1254	EP
O	1255	1260	group
O	1261	1264	and
B-cv-cont-median	1265	1266	7
I-cv-cont-median	1266	1267	.
I-cv-cont-median	1267	1268	1
I-cv-cont-median	1269	1275	months
O	1276	1279	for
O	1280	1283	the
O	1284	1286	EC
O	1287	1292	group
O	1293	1294	(
O	1294	1300	hazard
O	1301	1306	ratio
O	1307	1308	=
O	1309	1310	1
O	1310	1311	.
O	1311	1313	07
O	1313	1314	;
O	1315	1317	95
O	1317	1318	%
O	1319	1321	CI
O	1321	1322	,
O	1323	1324	0
O	1324	1325	.
O	1325	1327	92
O	1328	1330	to
O	1331	1332	1
O	1332	1333	.
O	1333	1335	24
O	1335	1336	;
O	1337	1338	P
O	1339	1340	=
O	1341	1342	.
O	1342	1344	41
O	1344	1345	)
O	1345	1346	,
O	1347	1350	and
B-outcome	1351	1357	median
I-outcome	1358	1365	overall
I-outcome	1366	1374	survival
I-outcome	1375	1379	time
O	1380	1383	was
B-iv-cont-median	1384	1386	13
I-iv-cont-median	1387	1393	months
O	1394	1397	for
O	1398	1401	the
O	1402	1404	EP
O	1405	1410	group
O	1411	1414	and
B-cv-cont-median	1415	1417	14
I-cv-cont-median	1418	1424	months
O	1425	1428	for
O	1429	1432	the
O	1433	1435	EC
O	1436	1441	group
O	1442	1443	(
O	1443	1449	hazard
O	1450	1455	ratio
O	1456	1457	=
O	1458	1459	1
O	1459	1460	.
O	1460	1462	02
O	1462	1463	;
O	1464	1466	95
O	1466	1467	%
O	1468	1470	CI
O	1470	1471	,
O	1472	1473	0
O	1473	1474	.
O	1474	1476	87
O	1477	1479	to
O	1480	1481	1
O	1481	1482	.
O	1482	1484	19
O	1484	1485	;
O	1486	1487	P
O	1488	1489	=
O	1490	1491	.
O	1491	1492	8
O	1492	1493	)
O	1493	1494	.

O	1495	1497	EP
O	1498	1506	patients
O	1506	1507	,
O	1508	1516	compared
O	1517	1521	with
O	1522	1524	EC
O	1525	1533	patients
O	1533	1534	,
O	1535	1538	had
O	1539	1543	more
B-outcome	1544	1549	grade
I-outcome	1550	1551	3
I-outcome	1552	1555	and
I-outcome	1556	1557	4
I-outcome	1558	1567	mucositis
O	1568	1569	(
B-iv-bin-percent	1569	1570	6
I-iv-bin-percent	1570	1571	%
O	1572	1573	v
B-cv-bin-percent	1574	1575	2
I-cv-bin-percent	1575	1576	%
O	1576	1577	,
O	1578	1590	respectively
O	1590	1591	;
O	1592	1593	P
O	1594	1595	=
O	1596	1597	.
O	1597	1601	0006
O	1601	1602	)
O	1603	1606	and
B-outcome	1607	1612	grade
I-outcome	1613	1614	3
I-outcome	1615	1618	and
I-outcome	1619	1620	4
I-outcome	1621	1634	neurotoxicity
O	1635	1636	(
B-iv-bin-percent	1636	1637	5
I-iv-bin-percent	1637	1638	%
O	1639	1640	v
B-cv-bin-percent	1641	1642	1
I-cv-bin-percent	1642	1643	%
O	1643	1644	,
O	1645	1657	respectively
O	1657	1658	;
O	1659	1660	P
O	1661	1662	<
O	1663	1664	.
O	1664	1668	0001
O	1668	1669	)
O	1669	1670	.

O	1671	1673	In
O	1674	1679	terms
O	1680	1682	of
B-outcome	1683	1694	progression
I-outcome	1694	1695	-
I-outcome	1695	1699	free
I-outcome	1700	1708	survival
I-outcome	1709	1712	and
I-outcome	1713	1720	overall
I-outcome	1721	1729	survival
O	1729	1730	,
O	1731	1736	there
O	1737	1740	was
O	1741	1743	no
O	1744	1752	evidence
O	1753	1755	of
O	1756	1757	a
O	1758	1768	difference
O	1769	1776	between
O	1777	1779	EP
O	1780	1783	and
O	1784	1786	EC
O	1786	1787	.

O	1788	1791	The
O	1792	1796	data
O	1797	1808	demonstrate
O	1809	1811	no
O	1812	1822	additional
O	1823	1832	advantage
O	1833	1835	to
O	1836	1841	using
O	1842	1844	EP
O	1845	1852	instead
O	1853	1855	of
O	1856	1858	EC
O	1859	1861	as
O	1862	1867	first
O	1867	1868	-
O	1868	1872	line
O	1873	1885	chemotherapy
O	1886	1889	for
O	1890	1893	MBC
O	1894	1896	in
O	1897	1903	taxane
O	1903	1904	-
O	1904	1906	na
O	1906	1907	Ã¯
O	1907	1909	ve
O	1910	1918	patients
O	1918	1919	.
